Soligenix Announces Formation of Behçet’s Disease Medical Advisory Board
Phase 2a clinical study of SGX945 in Behçet’s Disease initiating in 2024
PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the clinical development of SGX945 (dusquetide) for the treatment of Behçet’s Disease. The Company previously announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation for dusquetide in the treatment of oral lesions of Behçet’s Disease.
Related news for (SNGX)
- Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
- Don’t Miss Out: MoBot’s Latest Stock Updates 10/07/25 12:00 PM
- Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
- 24/7 Market News Snapshot 07 October, 2025 – Soligenix, Inc. Common Stock (NASDAQ:SNGX)
- Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma